DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Setting in Japan
NCT ID: NCT02226822
Last Updated: 2020-02-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1869 participants
OBSERVATIONAL
2014-09-20
2019-02-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Settings
NCT02322762
Cohort Study in Type 2 Diabetes in China
NCT01076023
Stromal Vascular Fraction and Autologous Activated Platelet-Rich Plasma Combination in Treating Treatment of Type 2 Diabetes
NCT05925829
Observational Study of ASCVD Risks of Type 2 Diabetes in East China
NCT04866667
Development of Minimally Invasive Methodology for Diabetyping to Personalise Treatment to Realise Remission and Reversal of Type 2 Diabetes
NCT06125119
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Adult patients with documented T2DM
Adult patients with documented history of type 2 diabetes mellitus who are initiating their second line oral or parenteral anti-diabetics medication after first line oral diabetic therapy
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Aged \> = 20 years
3. Diagnosed with type 2 diabetes mellitus
4. Initiating a second oral or parenteral anti-diabetic therapy added to oral anti-diabetic monotherapy or switching from the monotherapy to another monotherapy with different drug class
Exclusion Criteria
2. Current pregnancy
3. Current treatment for any cancer
4. Current dialysis treatment or renal transplantation
5. Current treatment with any oral steroids
6. Participation in any randomized control trials
7. Presence of any condition/circumstance which in the opinion of the investigator could significantly limit the complete follow up of the patient (e.g. tourist, non-native speaker who does not understand the local language where interpreter are not available, psychiatric disturbances, alcohol or drug abuse).
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ono Pharmaceutical Co. Ltd
INDUSTRY
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kiyoshi Hashigami, M.D.
Role: STUDY_DIRECTOR
AstraZeneca
Iichiro Shimomura, M.D., Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Department of Metabolic Medicine (Internal Medicine), Graduate School of Medicine, Osaka University
Hirotaka Watada, M.D., Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Department of Metabolism & Endocrinology, Graduate School of Medicine, Juntendo University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Anjo, Aichi-ken, Japan
Research Site
Anzai, Aichi-ken, Japan
Research Site
Komatsu, Aichi-ken, Japan
Research Site
Nagoya, Aichi-ken, Japan
Research Site
Hirosaki, Aomori, Japan
Research Site
Funabashi, Chiba, Japan
Research Site
Kisarazu, Chiba, Japan
Research Site
Tateyama, Chiba, Japan
Research Site
Matsuyama, Ehime, Japan
Research Site
Ono, Fukui, Japan
Research Site
Itoshima, Fukuoka, Japan
Research Site
Kitakyushu, Fukuoka, Japan
Research Site
Kurate-gun, Fukuoka, Japan
Research Site
Oguri, Fukuoka, Japan
Research Site
Ōnojō, Fukuoka, Japan
Research Site
Iwaki, Fukushima, Japan
Research Site
Shirakawa, Fukushima, Japan
Research Site
Isesaki, Gunma, Japan
Research Site
Kanra-gun, Gunma, Japan
Research Site
Shibukawa, Gunma, Japan
Research Site
Takasaki, Gunma, Japan
Research Site
Fukuyama, Hiroshima, Japan
Research Site
Asahikawa, Hokkaido, Japan
Research Site
Hakodate, Hokkaido, Japan
Research Site
Kamikawa, Hokkaido, Japan
Research Site
Muroran, Hokkaido, Japan
Research Site
Nakagawa, Hokkaido, Japan
Research Site
Otaru, Hokkaido, Japan
Research Site
Sapporo, Hokkaido, Japan
Research Site
Amagasaki, Hyōgo, Japan
Research Site
Kobe, Hyōgo, Japan
Research Site
Tamba, Hyōgo, Japan
Research Site
Hitachi, Ibaraki, Japan
Research Site
Koga, Ibaraki, Japan
Research Site
Ushiku, Ibaraki, Japan
Research Site
Kanazawa, Ishikawa-ken, Japan
Research Site
Komatsu, Ishikawa-ken, Japan
Research Site
Takamatsu, Kagawa-ken, Japan
Research Site
Kanoya, Kagoshima-ken, Japan
Research Site
Chigasaki, Kanagawa, Japan
Research Site
Hiratsuka, Kanagawa, Japan
Research Site
Isehara, Kanagawa, Japan
Research Site
Kamakura, Kanagawa, Japan
Research Site
Kawasaki, Kanagawa, Japan
Research Site
Yokohama, Kanagawa, Japan
Research Site
Hitoyoshi, Kumamoto, Japan
Research Site
Tamana, Kumamoto, Japan
Research Site
Ise, Mie-ken, Japan
Research Site
Tsu, Mie-ken, Japan
Research Site
Yokkaichi, Mie-ken, Japan
Research Site
Sendai, Miyagi, Japan
Research Site
Nichinan, Miyazaki, Japan
Research Site
Iida, Nagano, Japan
Research Site
Ueda, Nagano, Japan
Research Site
Kitakatsuragi-gun, Nara, Japan
Research Site
Jōetsu, Niigata, Japan
Research Site
Tomigusuku, Okinawa, Japan
Research Site
Urazoe, Okinawa, Japan
Research Site
Ikuno-ku, Osaka, Japan
Research Site
Kashihara, Osaka, Japan
Research Site
Sennan-gun, Osaka, Japan
Research Site
Toyonaka, Osaka, Japan
Research Site
Imari, Saga-ken, Japan
Research Site
Karatsu, Saga-ken, Japan
Research Site
Nishimatuura, Saga-ken, Japan
Research Site
Kasukabe, Saitama, Japan
Research Site
Sakado, Saitama, Japan
Research Site
Kouka, Shiga, Japan
Research Site
Kōka, Shiga, Japan
Research Site
Maibara, Shiga, Japan
Research Site
Ōtsu, Shiga, Japan
Research Site
Hamamatsu, Shizuoka, Japan
Research Site
Yaizu, Shizuoka, Japan
Research Site
Nasushiobara, Tochigi, Japan
Research Site
Oyama, Tochigi, Japan
Research Site
Shimotsuga-gun, Tochigi, Japan
Research Site
Edogawa-ku, Tokyo, Japan
Research Site
Hachiōji, Tokyo, Japan
Research Site
Kita-ku, Tokyo, Japan
Research Site
Koganei, Tokyo, Japan
Research Site
Kokubunji, Tokyo, Japan
Research Site
Mitaka, Tokyo, Japan
Research Site
Nerima-ku, Tokyo, Japan
Research Site
Shinagawa-ku, Tokyo, Japan
Research Site
Shinjuku, Tokyo, Japan
Research Site
Iwade, Wakayama, Japan
Research Site
Nakami, Yamagata, Japan
Research Site
Ube, Yamaguchi, Japan
Research Site
Kofu, Yamanashi, Japan
Research Site
Chiba, , Japan
Research Site
Fukui, , Japan
Research Site
Fukuoka, , Japan
Research Site
Gifu, , Japan
Research Site
Hiroshima, , Japan
Research Site
Kochi, , Japan
Research Site
Kumamoto, , Japan
Research Site
Kyoto, , Japan
Research Site
Miyazaki, , Japan
Research Site
Okayama, , Japan
Research Site
Osaka, , Japan
Research Site
Ōita, , Japan
Research Site
Saga, , Japan
Research Site
Shizuoka, , Japan
Research Site
Tochigi, , Japan
Research Site
Tokushima, , Japan
Research Site
Yamagata, , Japan
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Al Rubeaan K, Banah F, Alruwaily FG, Sheshah E, Alnaqeb D, AlQahtani AM, Ewais D, Al Juhani N, Hassan AH, Youssef AM. Metabolic control and incidence of hypoglycaemia, hospitalisation and complications among Saudi patients with type 2 diabetes initiating second-line therapy: an analysis of the Saudi Arabia data from the DISCOVER Observational Study programme. BMJ Open. 2023 Aug 30;13(8):e063586. doi: 10.1136/bmjopen-2022-063586.
Mita T, Katakami N, Takahara M, Kawashima M, Wada F, Akiyama H, Morita N, Kidani Y, Yajima T, Shimomura I, Watada H. Changes in Treatment Satisfaction Over 3 Years in Patients With Type 2 Diabetes After Initiating Second-line Treatment. J Clin Endocrinol Metab. 2022 Aug 18;107(9):2424-2432. doi: 10.1210/clinem/dgac420.
Hejjaji V, Gorgojo-Martinez JJ, Tang F, Garnelo JB, Cooper A, Medina J, Mutiozabal MS, Khunti K, Nicolucci A, Shestakova MV, Ji L, Gomes MB, Watada H, Vora J, Malik AO, Kosiborod M, Arnold SV. Factors associated with weight loss in people with overweight or obesity living with type 2 diabetes mellitus: Insights from the global DISCOVER study. Diabetes Obes Metab. 2022 Sep;24(9):1734-1740. doi: 10.1111/dom.14745. Epub 2022 May 25.
Takahara M, Mita T, Katakami N, Wada F, Morita N, Kidani Y, Yajima T, Shimomura I, Watada H; J-DISCOVER study group. Three-Year Glycaemic Control and Management in Patients with Type 2 Diabetes Initiating Second-Line Treatment in Japan: A Prospective Observational Study, J-DISCOVER. Diabetes Ther. 2022 Feb;13(2):251-264. doi: 10.1007/s13300-021-01192-x. Epub 2021 Dec 28.
Khunti K, Gomes MB, Kosiborod M, Nicolucci A, Pocock S, Rathmann W, Shestakova MV, Shimomura I, Watada H, Chen H, Cid-Ruzafa J, Fenici P, Hammar N, Tang F, Ji L; DISCOVER Scientific Committee and all DISCOVER investigators. Metformin discontinuation in patients beginning second-line glucose-lowering therapy: results from the global observational DISCOVER study programme. BMJ Open. 2020 Aug 30;10(8):e034613. doi: 10.1136/bmjopen-2019-034613.
Katakami N, Mita T, Takahara M, Yajima T, Wada F, Kawashima M, Shimomura I, Watada H; J-DISCOVER Study Group. Baseline Characteristics of Patients with Type 2 Diabetes Initiating Second-Line Treatment in Japan: Findings from the J-DISCOVER Study. Diabetes Ther. 2020 Jul;11(7):1563-1578. doi: 10.1007/s13300-020-00846-6. Epub 2020 Jun 5.
Khunti K, Chen H, Cid-Ruzafa J, Fenici P, Gomes MB, Hammar N, Ji L, Kosiborod M, Pocock S, Shestakova MV, Shimomura I, Tang F, Watada H, Nicolucci A; DISCOVER investigators. Glycaemic control in patients with type 2 diabetes initiating second-line therapy: Results from the global DISCOVER study programme. Diabetes Obes Metab. 2020 Jan;22(1):66-78. doi: 10.1111/dom.13866. Epub 2019 Oct 1.
Nicolucci A, Charbonnel B, Gomes MB, Khunti K, Kosiborod M, Shestakova MV, Shimomura I, Watada H, Chen H, Cid-Ruzafa J, Fenici P, Hammar N, Surmont F, Tang F, Pocock S. Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second-line therapy: Results from the global DISCOVER study programme. Diabetes Obes Metab. 2019 Nov;21(11):2474-2485. doi: 10.1111/dom.13830. Epub 2019 Aug 5.
Khunti K, Ji L, Medina J, Surmont F, Kosiborod M. Type 2 diabetes treatment and outcomes worldwide: A short review of the DISCOVER study programme. Diabetes Obes Metab. 2019 Nov;21(11):2349-2353. doi: 10.1111/dom.13817. Epub 2019 Jul 14.
Kosiborod M, Gomes MB, Nicolucci A, Pocock S, Rathmann W, Shestakova MV, Watada H, Shimomura I, Chen H, Cid-Ruzafa J, Fenici P, Hammar N, Surmont F, Tang F, Khunti K; DISCOVER investigators. Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program). Cardiovasc Diabetol. 2018 Nov 28;17(1):150. doi: 10.1186/s12933-018-0787-8.
Katakami N, Mita T, Takahara M, Hashigami K, Kawashima M, Shimomura I, Watada H; J-DISCOVER study group. Rationale and Design for the J-DISCOVER Study: DISCOVERing the Treatment Reality of Type 2 Diabetes in a Real-World Setting in Japan-A Protocol. Diabetes Ther. 2018 Feb;9(1):165-175. doi: 10.1007/s13300-017-0351-7. Epub 2017 Dec 19.
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D1692R00001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.